Market: NYQ |
Currency:
Address:
📈 LEN Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$98.25
-
Upside/Downside from Analyst Target:
15.48%
-
Broker Call:
-8
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
<0%
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for LEN
No earnings history available for this symbol.
📰 Related News & Research
-
Capstone Companies, Inc. Faces Transitional Challenges in 2025: Focus Shifts to New Business Development and Licensing After Connected Chef Setback
April 1, 2026
Capstone Companies, Inc. Annual Report 2025 - Key Highlights...
-
Key Business Risks, Competitive Advantages, and Regulatory Challenges Facing The OLB Group, Inc. in the E-Commerce and Digital Asset Markets
April 1, 2026
OLB Group, Inc. 2025 Annual Report - Investor Key Points ...
-
TherapeuticsMD 2025 Annual Report: Business Overview, Risk Factors, and Intellectual Property Challenges
April 1, 2026
TherapeuticsMD, Inc. 2025 Annual Report: Key Highlights for ...
-
Helens International Holdings 2025 Annual Results: Revenue, Profit Recovery & Final Dividend of RMB0.0554 Per Share
April 1, 2026
Helens International Holdings Company Limited: FY2025 Annual...
-
LENSAR Reports Strong 2025 Results: ALLY Robotic Cataract Laser Adoption Grows, Recurring Revenue Hits $46.3M
March 31, 2026
LENSAR, Inc. Reports Q4 and Full Year 2025 Financial Results...
-
KeyBank and Lenders Establish Credit Agreement with Cintas Corporation – Terms, Definitions, and Financial Covenants Explained
March 31, 2026
Cintas Corporation No. 2 - Credit Agreement and Material Eve...
-
21Shares XRP ETF (TOXR) Annual Report: Key Risks, Regulatory Challenges, and Market Factors Impacting XRP Investments
March 31, 2026
21Shares XRP ETF Annual Report: Key Investor Insights 21...
-
Galectin Therapeutics 2025 Annual Report: Clinical Trials, Regulatory Challenges, and Biopharma Industry Risks
March 31, 2026
Galectin Therapeutics 2025 Annual Report: Key Highlights for...
-
Ensysce Biosciences, Inc. — Business Overview, Risk Factors, Regulatory Approvals, and Intellectual Property Challenges 64
March 31, 2026
Ensysce Biosciences, Inc. Annual Report Analysis Ensysce...
-
Siebert Financial Corp. Expands Financial Services, Technology, and Media Offerings Amid Competitive Market and Cybersecurity Challenges 131417304961
March 31, 2026
Siebert Financial Corp 2025 Annual Report: Key Insights for ...
🔍 View more Reports